Improved detection of multiple sclerosis gadolinium-enhancing lesions: 3D T1 Turbo-Spin-Echo Outperforms 3D T1 Turbo-Field Echo MRI

Competing Interest Statement

The institution where Sergio Martinez-Yelamos and Antonio Martinez-Yelamos work (Hospital Universitari de Bellvitge / Institut d'Investigacio Biomedica de Bellvitge) has received, in the last 3 years and exclusively to support the research of the Unit, advisory fees, collaboration funds, donations, or consultancy payments from the following companies: Almirall, Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Horizon/Amgen, Janssen, Kern Pharma, Lilly, Merck, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi.

Funding Statement

This study received funding from the Institut de Diagnostic per la Imatge (IDI) under the reference PREDOC IDI 22, dated October 3, 2022. The funding was specifically allocated for manuscript proofreading.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Research Ethics Committee of Bellvitge University Hospital (reference PR192/24). The requirement for informed consent was waived due to the retrospective observational nature of the study and compliance with national and European Union regulations. All data were anonymized prior to analysis.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes